765278-73-7 Usage
Uses
Used in Chiral Station Phases Preparation:
(S)-(-)-3,3'-Dibromo-5,5',6,6',7,7',8,8'-octahydro-1,1'-bi-2,2'-naphthalenediol, 97% is used as a reagent for the preparation of peptoid-modified silica gel chiral stationary phases. The chiral nature of (S)-(-)-3,3'-Dibromo-5,5',6,6',7,7',8,8'-octahydro-1,1'-bi-2,2'-naphthalenediol, 97% allows it to interact with other chiral molecules, making it an essential component in the development of chiral stationary phases.
Used in HPLC Enantioseparations:
In the field of chromatography, (S)-(-)-3,3'-Dibromo-5,5',6,6',7,7',8,8'-octahydro-1,1'-bi-2,2'-naphthalenediol, 97% is utilized for high-performance liquid chromatography (HPLC) enantioseparations. (S)-(-)-3,3'-Dibromo-5,5',6,6',7,7',8,8'-octahydro-1,1'-bi-2,2'-naphthalenediol, 97%'s ability to selectively interact with enantiomers, or mirror-image isomers of chiral molecules, enables the efficient separation of these isomers, which is crucial in various applications such as pharmaceutical development, where the desired biological activity may be associated with only one enantiomer.
Used in Pharmaceutical Industry:
(S)-(-)-3,3'-Dibromo-5,5',6,6',7,7',8,8'-octahydro-1,1'-bi-2,2'-naphthalenediol, 97% can be used in the pharmaceutical industry for the development of chiral drugs. (S)-(-)-3,3'-Dibromo-5,5',6,6',7,7',8,8'-octahydro-1,1'-bi-2,2'-naphthalenediol, 97%'s role in chiral stationary phases and its ability to separate enantiomers can help in the synthesis and purification of single-enantiomer drugs, which can lead to improved efficacy and reduced side effects.
Used in Research and Development:
In the research and development sector, (S)-(-)-3,3'-Dibromo-5,5',6,6',7,7',8,8'-octahydro-1,1'-bi-2,2'-naphthalenediol, 97% can be employed for studying the properties and behavior of chiral compounds. Its use in HPLC enantioseparations can aid researchers in understanding the interactions between chiral molecules and chiral stationary phases, which can contribute to the advancement of chiral chromatography techniques and the development of new chiral compounds.
Check Digit Verification of cas no
The CAS Registry Mumber 765278-73-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 7,6,5,2,7 and 8 respectively; the second part has 2 digits, 7 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 765278-73:
(8*7)+(7*6)+(6*5)+(5*2)+(4*7)+(3*8)+(2*7)+(1*3)=207
207 % 10 = 7
So 765278-73-7 is a valid CAS Registry Number.
765278-73-7Relevant academic research and scientific papers
Cu-Catalyzed Diastereo- and Enantioselective Reactions of γ,γ-Disubstituted Allyldiboron Compounds with Ketones
Meek, Simon J.,Zanghi, Joseph M.
supporting information, p. 8451 - 8455 (2020/04/22)
A catalytic diastereo- and enantioselective method for the preparation of complex tertiary homoallylic alcohols containing a vicinal quaternary carbon stereogenic center and a versatile alkenylboronic ester is disclosed. Transformations are promoted by 5 mol % of a readily available copper catalyst bearing a bulky monodentate phosphoramidite ligand, which is essential for attaining both high dr and er. Reactions proceed with a wide variety of ketones and allylic 1,1-diboronate reagents, which enables the efficient preparation of diverse array of molecular scaffolds.
Enantioselective hydroformylation by a Rh-catalyst entrapped in a supramolecular metallocage
Garca-Simn, Cristina,Gramage-Doria, Rafael,Raoufmoghaddam, Saeed,Parella, Teodor,Costas, Miquel,Ribas, Xavi,Reek, Joost N. H.
supporting information, p. 2680 - 2687 (2015/03/04)
Regio- and enantioselective hydroformylation of styrenes is attained upon embedding a chiral Rh complex in a nonchiral supramolecular cage formed from coordination-driven self-assembly of macrocyclic dipalladium complexes and tetracarboxylate zinc porphyrins. The resulting supramolecular catalyst converts styrene derivatives into aldehyde products with much higher chiral induction in comparison to the nonencapsulated Rh catalyst. Spectroscopic analysis shows that encapsulation does not change the electronic properties of the catalyst nor its first coordination sphere. Instead, enhanced enantioselectivity is rationalized by the modification of the second coordination sphere occurring upon catalyst inclusion inside the cage, being one of the few examples in achieving an enantioselective outcome via indirect through-space control of the chirality around the catalyst center. This effect resembles those taking place in enzymatic sites, where structural constraints imposed by the enzyme cavity can impart stereoselectivities that cannot be attained in bulk. These results are a showcase for the future development of asymmetric catalysis by using size-tunable supramolecular capsules.
